Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/22218
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSchmidt, Andrew-
dc.contributor.authorAzad, Arun-
dc.contributor.authorGoh, Jeffrey-
dc.contributor.authorHarris, Carole-
dc.contributor.authorJoshua, Anthony M-
dc.contributor.authorWeickhardt, Andrew-
dc.contributor.authorKrieger, Laurence-
dc.date.accessioned2019-12-04T05:00:32Z-
dc.date.available2019-12-04T05:00:32Z-
dc.date.issued2019-11-
dc.identifier.citationAsia-Pacific journal of clinical oncology 2019; 15 Suppl 10: 3-10-
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/22218-
dc.description.abstractVascular endothelial growth factor receptor tyrosine kinase inhibitors have provided an effective standard of care for the treatment of metastatic clear cell renal cell carcinoma (mRCC). Survival is prolonged with emergence of modern immuno-oncology combination regimens. Prognostic risk assessment is essential for choosing between these therapies to determine the most appropriate first line treatment option, with selection based on International Metastatic RCC Database Consortium Risk Category. We review the current subsidized first line treatments for mRCC in Australia and consider the evidence for treatment selection and sequencing.-
dc.language.isoeng-
dc.subjectVEGF tyrosine kinase inhibitors-
dc.subjectimmuno-oncology-
dc.subjectrenal cell carcinoma-
dc.titleTreatment selection for first-line metastatic renal cell carcinoma in Australia: Impact of new therapy options.-
dc.typeJournal Article-
dc.identifier.journaltitleAsia-Pacific journal of clinical oncology-
dc.identifier.affiliationLiz Plummer Cancer Centre, Cairns, Queensland, Australia-
dc.identifier.affiliationPeter McCallum Cancer Centre, Melbourne, Victoria, Australia-
dc.identifier.affiliationRoyal Brisbane and Women's Hospital, Butterfield Street, Herston & University of Queensland, St Lucia, Queensland, Australia-
dc.identifier.affiliationSt George Hospital and Sutherland Clinical School UNSW, Kogarah, New South Wales, Australia-
dc.identifier.affiliationThe Kinghorn Cancer Centre, Darlinghurst, New South Wales, Australia-
dc.identifier.affiliationOlivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia-
dc.identifier.affiliationRoyal North Shore Hospital, Reserve Rd, St Leonards, Northern Cancer Institute, St. Leonards, New South Wales, Australia-
dc.identifier.doi10.1111/ajco.13289-
dc.identifier.pubmedid31762165-
dc.type.austinJournal Article-
local.name.researcherSchmidt, Andrew
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.languageiso639-1en-
item.openairetypeJournal Article-
crisitem.author.deptMedical Oncology-
crisitem.author.deptOlivia Newton-John Cancer Wellness and Research Centre-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

8
checked on Mar 28, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.